More Support for Dual Antithrombotic Therapy After PCI in Patients with Atrial Fibrillation

In a small randomized trial, dual therapy with edoxaban plus P2Y₁₂ inhibition was noninferior to triple therapy with warfarin, P2Y₁₂ inhibition, and aspirin.

In the wake of several randomized trials evaluating short-term anticoagulation strategies for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI; e.g., NEJM JW Cardiology Jan 2017 and N Engl J Med 2016; 375:2423), another has been published (NCT02866175). Edoxaban's manufacturer funded the trial.

The researchers randomized 1506 adults with AF undergoing PCI to one of two regimens:

Edoxaban plus a P2Y₁₂ inhibitor for 12 months
Warfarin plus a P2Y₁₂ inhibitor for 12 months, in addition to aspirin for 1 to 12 months

For the primary endpoint — major bleeding or clinically relevant nonmajor bleeding within 12 months — the annualized event rate in the dual-therapy group was noninferior to that in the triple-the…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

More Support for Dual Antithrombotic Therapy After PCI in Patients with Atrial Fibrillation

Topics

Reviewing Author